According to an international survey conducted earlier this year, 70% of respondents said they believed tobacco companies make money by selling devices such as inhalers, medication or other equipment to treat lung diseases. The survey findings are published in a new communication brief entitled "Pharmaceutical industry ownership of the tobacco business: An international survey of respiratory disease patients", in the official journal of the British Thoracic Society, Thorax.
At the beginning of 2022, a total of 1,196 individuals who reported using inhalers participated in a survey. Following the acquisition of pharmaceutical company Vectura by Fimo International in 2021, patient advocacy groups sought to understand patients' attitudes towards tobacco companies holding stakes in manufacturers of respiratory inhalation equipment. Vectura has developed several widely-used medical delivery devices and/or formulations for inhalation therapy for chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and asthma.
The COPD Foundation, in collaboration with the Global Allergy and Airways Patient Platform and Lung Foundation Australia, conducted a survey of chronic lung disease patients in January through March 2022 in English, Spanish, and German. In addition to expressing concerns about tobacco ownership of lung treatments, a significant portion (48%) of surveyed patients also indicated that they would strongly consider switching inhalers if they knew tobacco companies manufactured or sold the brand they use.
This was an unexpected discovery, as in my own practice, many patients have expressed a tendency to stick with medications that are effective for them," said Byron Thomashow, Chief Medical Officer of the COPD Foundation and co-author of the Chest brief, in a statement. "However, socioeconomic and systemic factors, such as insurance coverage, healthcare system restrictions, and convenience, strongly impact a patient's ability to make treatment choices.
Statement
This article is compiled from third-party information and is intended for industry professionals for the purposes of learning and sharing information.
This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness or accuracy of the article's content. The translation of this article is only intended for industry communication and research purposes.
Due to limitations in the level of translation, the translated article may not fully express the original text, therefore please refer to the original text for accuracy.
2FIRSTS maintains full alignment with the Chinese government in regard to any domestic, Hong Kong, Macau, Taiwan, or foreign issues and stances.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.
This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.
